Home Tags Metastatic Urothelial Cancer

Tag: Metastatic Urothelial Cancer

ASCO 2020 – Advancing Antibody-drug Conjugates: Sacituzumab Govitecan

With a growing number of antibody-drug conjugates being approved by regulatory agencies around the world and promising clinical benefits seen in investigational agents, the...
Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seattle Genetics file BLA for Enfortumab Vedotin

Japanese drugmaker Astellas Pharma and Seattle Genetics confirmed the submission of a Biologics License Application (BLA) for accelerated approval to the U.S. Food and...
ESMO 2017 - 3

Interim Phase II Results with Sacituzumab Govitecan in Pretreated Metastatic Urothelial...

Results from an interim Phase II study with sacituzumab govitecan (IMMU-132) shows that the investigational agent is active in patients with metastatic urothelial cancer...

Promising Phase I Data for Enfortumab Vedotin (ASG-22ME) and ASG-15ME in...

The annual congress of the European Society of Medical Oncology (ESMO), this year held in Copenhagen, Denmark (October 7 - 11, 2016) is the premier...